Geron and BTX down down down

BioTime was down big, 33 cents to close at $4.53 on 420,000 shares. People are finally seeing that they have no money, and only about $1-2 million coming in and ten times that amount going out. I still like the company's vision and goals, but they will need billions of dollars to make those goals and visions come true. I will buy a little more under $4.........Geron down 14 cents at $1.49 on 1 million shares. They have more money then BTX but only one possible product that will need 2 more years of trials. Happy I sold most of my shares. .....ACTC up at 8 cents, they need money, results and a partner soon, may buy more under 7 cents for a quick trade..... AAPL at $456.91, all I can say is the market is crazy, Amazon missed earnings and it went up. AAPL missed just a little and down it went, it's PE is around 10 and Amazon is over 80 un-real....Good luck in this rigged casino,

AAPL dives

I'm so gald I only have a few shares of AAPL, down $63.51 on very heavy volume of 52.2 million shares, so I only lost 2Gs on paper. .......Geron was down 1 cent to close at $1.64 on light volume of 645,171 shares, no news.....ACTC down under 8 cents at 0.0781, no news. BTX unchanged at $4.76 on avg. volume, no news. ...Good luck in this rigged casino.

BTX up again

BioTime was up 3 cents at $4.76, on good volume of 430,358 shares the three month avg. is 194,992 shares. I went to there website to hear the Lastest Information I clicked it on. It was on ECI Scale-up and Manufacturing of Cell Based Therapies II. I didn't understand it at all. Went and click the latest video, Product Development Update: Life Map Discovery, much better, I like what they are doing. But I wish I knew were the money is going to come from to run the trials. I will buy a few more shares, not many, been burned too many times............................................. AAPL earnings missed, all hope is gone, will washout at around $325 then if they can come up with new products that we all have to have, it will do a slow climb to $450, maybe. ...............Good luck in this rigged casino

BioTime back up

BioTime closed up 12 cents on very good volume of 459,511 shares, the three month avg. is 181,492 shares. Something is up with them, it may be good and it may be bad. The volume and price action say good for know. After losing more money then I care to think about over the 30 years of gambling and it is a gamble it could be bad....Good luck in this rigged casino,

Patients with Better Vision to be Enrolled in ACTC

Patients with Better Vision to be Enrolled in ACT's Clinical Trials for Macular Degeneration Jan 22, 2013 08:30:02 (ET) MARLBOROUGH, Mass., Jan 22, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, announced today that it is amending the patient treatment protocol for the remainder of the Company's Phase I clinical trials for Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) currently being conducted in the U.S. and will also submit an amendment in Europe for the SMD trial being conducted there. Patients with better vision, a visual acuity of 20/100, will be eligible for enrollment in the remainder of the trials. By treating patients earlier in the course of the disease, the Company believes that the amended patient protocol will have a more significant impact on photoreceptor rescue and visual function. In previous protocols, only SMD patients with a visual acuity no better than hand movement in the treated eyes and dry AMD patients with a visual acuity of 20/400 were eligible. "Having recently reached the halfway point in our three clinical trials for macular degeneration, now is an opportune time to pursue modifications which could help accelerate the pace of all three trials," said Gary Rabin, chairman and CEO. "The advanced age of many of our enrolled patients has tended to limit the pace at which we are able to enroll and treat them, since other, unrelated health complications tend to come up more frequently in the elderly. Patients with better vision tend to be younger on average." The Company plans to institute the amended patient protocols upon receipt of Institutional Review Board (IRB) approval from each of the clinical sites, for the second half of all the clinical trials. "We are pleased to be able to expand patient enrollment in all three of our ongoing clinical trials," said Robert Lanza, M.D., ACT's chief scientific officer. "Not only does it have the potential to accelerate the road to the completion of Phase I, but having a more diverse patient population could also provide additional clinical insights." Good news stock was up a little. Good luck in this rigged casino.

BTX down 3rd day

BioTime is down again 8 cents at $4.61, on 494,198 shares. The three month avg. volume is 173,844. ....................ACTC had a good day, Thursday they stated there last law suit was settled for 12.5 million dollars, most of it will be in stock. They have $8 million in the bank. You would think the share price would go down. BUT NO it went up and closed at 0.0881 on 21.5 million shares. The three month avg. is 8.7 million shares. .................Good luck in this rigged casino.

BTX down again 2nd day

Well all good things must come to an end. BTX closed down 19 cents at $4.69 on 465,140 shares. The 3 month avg. volume is 166,466 shares. I think this was a pump and dump. The big boys run the stock up, buy calls, selling them before they dump and buying puts before they dump. Then sell the puts way they drive the price down by dumping the shares. Making alot of money on the way up and on the way down...........Good luck in this rigged casino,

BioTime down first time in 7 days

What a great run, from $3.20 on Jan. 4th to $4.99 on Jan. 15th. BTX closed down 11 cents today at $4.88 on 563,755 shares. The three month avg. volume is 166,466 shares. Still do not know how BioTime is going to get the money for the stem cell trials without sell more shares, that will drive the share price down...........ACTC closed at 0.0858 on 5.7 million shares. The three month avg. volume is 8.7 million shares......................Geron closed down 9 cents at $1.64 on 877,450 shares the three month avg. volume is 1.2 million shares......................................All three companys need money and or great results from there trials, without that they will all go down.............................................Good luck in this rigged casino,

Amazing BTX up 7 days in a row

BioTime closed uo again 20 cents at $4.99 on great volume of 615,523 shares. I think we will slow down over $5. Remember I said it would go up, because I sold a covered call at $5 for June.......................ACTC was down a little at 0.085 on 7.5 million shares, the three month avg. is 8.7 million shares...........Geron was up 2 cents at $1.73 on just under 1 million shares........... The deal between BioTime and Geron is going to be done in Sept 2013. It will be a long 7 months..............Good luck in this rigged casino,

ACTC the future in bio-tech: BTX up 6 days in a row

ACTC the future in bio-tech: BTX up 6 days in a row: WOW! Up again 27 cents to close at $4.79 on 1 million + shares WOW. The three month avg. volume is 133,543. We go higher, I can guarantee it...

BTX up 6 days in a row

WOW! Up again 27 cents to close at $4.79 on 1 million + shares WOW. The three month avg. volume is 133,543. We go higher, I can guarantee it, because I sold a $5 June covered called. With my luck it will hit $6 by June. I can find nothing in the news that will bring them any money in quickly. A lot of feel good news, yea it works great in mice, but in people, that's years away. BTX will need money soon. How will they get it? Most likely a 2nd offering that will delute the share price..............ACTC was up a little at 0.087 on 10.6 million shares. The three month avg volume is 8.5 million shares. Need good news, need partner. ............................Geron up 5 cents to close at $1.71 ON 1.3 million shares. The three month avg. volume is 1.1 million shares......... .........................Good luck is this rigged casino.

BTX up 5 days in a row

BioTime just keeps going up and I don't know why? From $3.20 on Jan 4th to $4.52 on Friday Jan 11th. Volume was 542,252 shares, the three month avg. volume is 125,075. I like the companys setup with 7 companys, they can sell one or go public with one. The problem now is money, they need money and yet the stock goes up........................................................................................................Geron was down 1 cent to close at $1.66 on light volume................ ,.,.,.ACTC was up a little to close at 0.0812 on avg. volume. All three companys need money within about 2 years..............................................Good luck in this rigged casino,

BioTime submits protocol for initiation of human clinical trials of Renevia in Europe

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical Investigation Protocol (CIP) to European regulatory authorities for approval to initiate studies for its Renevia™stem cell delivery platform. The Principal Investigator for the studies will be Ramon Llull, MD, and the planned trials will be conducted at the Stem Center, Palma de Mallorca, Spain (www.stem-center.com). The Stem Center is operated by the GID Group, Inc., of Louisville, Colorado. BioTime is currently completing the production of clinical materials according to current Good Manufacturing Practice regulations. The initiation of human clinical studies is expected in Q2 of this year upon approval of the CIP. Renevia™, a member of the Company’s HyStem® family of hydrogels, is a proprietary formulation that mimics the human extracellular matrix, a web of molecules surrounding cells that is essential to cellular function. Renevia™ is designed to be a liquid injectable matrix capable of safely polymerizing in the body into a three-dimensional tissue-like scaffold in combination with transplanted cells. Anchoring the transplanted cells in such a biocompatible matrix generally increases the percentage of viable cell engraftment. HyStem® hydrogels are currently being used by researchers at a number of leading medical schools in laboratory studies to investigate a broad array of stem cell therapies, including wound healing, treatment of ischemic stroke, brain cancer, vocal fold scarring, and cardiac infarct. Videos describing the technology by the inventor Glenn Prestwich, PhD, are available for viewing online at www.biotimeinc.com/corporate-videos/. “This is an important step forward in our commercialization efforts and brings us closer to delivering this much-needed matrix technology for the emerging field of regenerative medicine,” stated William P. Tew, PhD, Chief Commercialization Officer of BioTime, Inc. “The technology forms a foundation for the delivery of cell-based therapeutic products in both the adult and embryonic stem cell marketplace. Current preclinical studies at leading medical institutions have shown that HyStem®hydrogels are compatible with a wide variety of tissue types including brain, bone, skin, nerve, cartilage, and heart.” In the clinical application described in this CIP, Renevia™ will be used as a delivery matrix for autologous adipose cells in order to restore subcutaneous tissue lost as a result of injury, oncologic resection, or congenital defects. Restoration of the normal skin contour is an important quality-of-life issue, not only in elective cosmetic procedures, but also in reconstructive surgeries needed to repair deformities and traumatic injuries to the face and upper extremities. BioTime’s plan is to bring Renevia™ to the medical market first in the European Union, where the regulatory pathway will allow for faster approval. Once the use of Renevia™ is established in Europe, BioTime plans to address an even larger potential market in the United States. Evaluation of Renevia™ in ISO 10993 biocompatibility studies has been successfully completed as prescribed by the International Organization for Standardization for permanent implantable medical devices. This testing is required by the United States Food and Drug Administration and European Union regulatory authorities prior to the initiation of clinical studies in humans. The results of these preclinical studies successfully demonstrated the safety and biocompatibility of Renevia™. ....... ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, BTX is up again to $4.43 on 3xs the normal volume. I have only 100 share, wish I'd bought more. BTX may soon be the future in bio-tech. I will slowly buy more shares, when it drops and it will drop. Most like after I buy. ............................... Good luck in this rigged casino,

BTX up again

BioTime up again, 30 cents to close at $4.18 on huge volume of 985,959 shares. The three month avg. volume is 118,479 shares. ............................Geron up one cent to close at $1.64 on 788,531 shares. The three month avg. volume is 1.1 million shares............ACTC down a liitle at 0.08 cents on 18.4 million shares. the three month volume is 8.3 million shares.........................Amazing that BioTime is still going up and ACTC still going down.....................Good luck in this rigged casino.

BioTime up big

I do not understand why BioTime is up again today and ACTC is down. BioTime needs 50 million dollars just to finish Phase 1 trials on Geron's [now BioTime's] acute spiral cord injuries. ACTC had great results at the half way mark, of there Phase 1/2 trials and they closed down.......BTX closed up 43 cents at $3.88 on outstanding volume of 581,946 shares, the three month avg. volume is 104,146 shares. .....ACTC was down under 9 cents at 0.082 on 46,081,681 shares wow! The three month avg is 8.3 million shares.....Geron was up 3 cents to close at $1.63 on only 470,695 shares. The three month avg. is 1.1 million shares. ....Good luck in this rigged casino,

ACTC Achieves Clinical Milestone: Up again

Advanced Cell Technology Achieves Clinical Milestone Font size: A | A | A 8:30 AM ET 1/8/13 | BusinessWire Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, announced today that investigators for the Company's Phase I/II clinical trials for Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) have observed evidence of engraftment of the transplanted human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells and visual acuity gain in patients treated over the 18 months since the trials were first initiated. The Company believes this observation of engraftment and persistence is clinically important because engraftment of cells in the proper area, and recapitulation of normal RPE cell layer structure is important to the ultimate efficacy of the RPE cells in the treatments. Additionally, investigators have not observed any issues of safety relating to the transplanted human embryonic stem cell (hESC)-derived RPE cells in any of the 18 patients treated. The company believes this warrants early (though cautious) optimism as the company looks forward to initiating the second half of the three trials. "Now that we are at the halfway point in all three of our ongoing trials, we have had the opportunity to stop and assess not only the data relating to safety, but also to the activity of the transplanted RPE cells," said Gary Rabin, chairman and CEO. "In our first report of hESC-derived cells transplanted into patients, published in the Lancet, we reported no adverse safety signals and that both patients that had been treated by that point showed some signs of visual improvements. For both of those patients, those gains in visual acuity have persisted for nearly 18 months now. In addition, we have observed persisting engraftment of the transplanted RPE cells in our more recent SMD and dry AMD patients. This is the first time we have shown this in dry AMD patients, which we find particularly encouraging, given that dry AMD represents one of the largest unmet medical needs in the world." "We are optimistic about the prospects of our RPE cells ultimately impacting positively on various forms of macular degeneration," said Robert Lanza, M.D., ACT's chief scientific officer. "As we have added additional clinical trial sites, the pace of patient treatments has picked up. At the same time, we are extending our observations to a greater number of patients, as well as collecting data over extended periods of time after the surgery." Mr. Rabin will be providing an overview of the company's progress, including providing some representative examples of anatomical data of RPE engraftment in the trials, in his presentation on Tuesday, Jan. 8 at Biotech Showcase 2013 in San Francisco. Pictures of the engraftment will be included in Mr. Rabin's presentation, which will be posted to the Presentations section of the ACT site, and a link to a webcast of the presentation will be available on the Events section. Great news, should move up to 10 cents................................................ ......................................................................................................................................................................................................................................................................Good luck in this rigged casino,

Great day for BTX and ACTC

BTX picked up 400 patents dealing with human embryonic stem cells from Geron. BTX was up 25 cents to close at $3.45. The volume was 268,062 shares. The three month avg. volume is 95,221 shares. BTX needs $500,000,000 [just a guess] to finish the trials on the acute spiral cord injuries. They have around $20 million. I think they will be taking donations....................................................................... ACTC up big to close at 0.0899 an huge volume of 73,331,184 shares. The three month avg. is 6.6 million shares. CEO Gary Rabin will present at Biotech Showcase, Jan. 8 in San Francisco.......................................................................... Geron was up 2 cents to close at $1.60 on only 877,078 shares. ........................ Good luck in this rigged casino,

BioTime done deal with Geron. ACTC up big again

What a great day! BioTime signs definitive agreement with Geron regarding stem cell assets. BTX up 10% and Geron up 2 cents. This is great news, the Phase 1 trial should start again. That's the one trying to repair acute spiral cord injuries, yea baby. So BioTime is now the future in bio-tech, you heard it here first...................... ............................................................................................................................................................................................................................................................................................................................................................ACTC up big again over 9 cents. No news, thinking it's coming very soon, maybe Tuesday Jan. 8th the CEO is speaking.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Good luck in this rigged casino,

ACTC up 31% YEA BABY

ACTC up 31% on heavy volume to close at 0.0799. Looked for news, nothing great. Thinking maybe more good results on Phase 1/2 trials, are coming out soon. ACTC volume was 25.5 million shares, the three month avg. 6.4 million shares.........Geron was up 5 cents to close at $1.58 on only 756,396 shares. No news, only have a few shares like, so with my luck Geron should hit $5 this year..... Good luck in this rigged casino,